Announcements Trials
Browse Landscape

Phase

Phase 3 6Phase 2 6Phase 1 4Phase NA 3Phase 1/2 2

Status

Completed 6

Sponsor Class

INDUSTRY 5UNKNOWN 1

Study Type

Interventional 6

Sponsor

Conditions

Pain 6Cancer Pain 4Neoplasms 2

Interventions

Cisplatin 725Carboplatin 607Paclitaxel 578Cyclophosphamide 516Radiotherapy 511Docetaxel 475Fluorouracil 453Gemcitabine 437Doxorubicin 383Capecitabine 361Dexamethasone 327Oxaliplatin 288pembrolizumab 283Leucovorin 282Bevacizumab 275Etoposide 271Vincristine 270Rituximab 246Prednisone 222Pemetrexed 217Cytarabine 205Drug Therapy 194Trastuzumab 175Irinotecan 172Methotrexate 171Lenalidomide 137Nivolumab 135Filgrastim 135Epirubicin 129Tamoxifen 127

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × Interventional × nabiximols × Clear all
NCT00674609 2023-05-03

SPRAY

Jazz Pharmaceuticals

Phase 3 Completed
177 enrolled 21 charts

Neoplasms, Pain

NCT00675948 2023-05-03

Study to Compare the Safety and Tolerability of Sativex® in Patients With Cancer Related Pain

Jazz Pharmaceuticals

Phase 3 Completed
43 enrolled 11 charts

Neoplasms, Pain

NCT01337089 2023-04-12

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

Jazz Pharmaceuticals

Phase 3 Completed
660 enrolled 9 charts

Cancer Pain, Pain

NCT01361607 2023-04-12

SPRAY III

Jazz Pharmaceuticals

Phase 3 Completed
399 enrolled 17 charts

Cancer Pain, Pain

NCT01424566 2023-04-12

A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer

Jazz Pharmaceuticals

Phase 3 Completed
406 enrolled 16 charts

Cancer Pain, Pain

NCT01262651 2018-04-23

Sativex® for Relieving Persistent Pain in Participants With Advanced Cancer

GWPharm

Phase 3 Completed
397 enrolled 18 charts

Cancer Pain, Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡